Brief: Nanobiotix Presents First Data From Study On NBTXR3 For Patients With Locally Advanced Pancreatic Cancer

Nanobiotix SA

28/09/2023 23:12

Sept 28 (Reuters) - Nanobiotix SA  NANOB.PA :
    * NANOBIOTIX ANNOUNCES PRESENTATION OF FIRST DATA FROM PHASE
1
STUDY EVALUATING NBTXR3 FOR PATIENTS WITH LOCALLY ADVANCED
PANCREATIC CANCER
    * NANOBIOTIX-DATA SHOW LOCAL ENDOSCOPIC INJECTION OF NBTXR3
FOLLOWED BY RADIOTHERAPY ACTIVATION REMAINS FEASIBLE WITH
TOLERABLE SAFETY PROFILE IN 15 PATIENTS
    * NANOBIOTIX SA - PRELIMINARY RESULTS FROM ONGOING STUDY
SHOWED
MEDIAN OVERALL SURVIVAL OF 21 MONTHS FROM DIAGNOSIS IN EVALUABLE
POPULATION

Source text for Eikon:  ID:nGNX9YfwVL 
Further company coverage:  NANOB.PA 
    
    

 ((Reuters.Briefs@thomsonreuters.com;;))